Literature DB >> 22386140

Inferior vena cava resection and reconstruction for retroperitoneal tumor excision.

William Quinones-Baldrich1, Ali Alktaifi, Fritz Eilber, Frederick Eilber.   

Abstract

OBJECTIVE: This study reviews the results of en bloc resection of the inferior vena cava (IVC) for malignant tumor excision and reconstruction.
METHODS: A prospective database was reviewed. IVC resection was categorized as suprarenal, perirenal, infrarenal, or extensive (>one segment resected). Repairs were divided into primary, patch, or circumferential. Tumor type, perioperative morbidity, mortality, and graft patency were recorded.
RESULTS: Between 1990 and 2011, 47 patients (21 women; mean age, 56; range, 35-89 years) underwent IVC resection for en bloc tumor excision. Sarcomas were most common (36 [77%]: 30 primary IVC). Eleven patients had primary IVC repair, nine patch repair (two autogenous), and 27 had circumferential replacement with a polytetrafluoroethylene ringed graft. Extensive IVC reconstruction in 18 patients included the entire IVC, with renal (RV) and hepatic vein reimplantation in eight; suprarenal and perirenal in six (seven RVs reimplanted); and infrarenal and perirenal in four (four RVs reimplanted). Nine single-segment IVC replacements were infrarenal. Morbidity was 10.6%: one each with bowel obstruction, chyle leak, renal failure with complete recovery (left RV reimplant, right nephrectomy), reoperation for bleeding, and IVC graft thrombosis. Morbidity did not differ by type of reconstruction. There was no mortality. Follow-up ranged from 1.5 to 216 months (18 years) with a mean of 3.5 years. Computed tomography or duplex scans were available in 28 of 47 patients and in 15 of 27 patients in group 3 at a mean follow-up of 36 and 20 months, respectively. One IVC graft thrombosis was documented at 10 months after chemotherapy/sepsis. Tumor recurrence caused three graft stenoses. Cumulative 5-year patency in group 3 was 80% (imaging) and 92% (clinical). Lower extremity edema was universally avoided. Cumulative 5-year survival for the series was 45% ± 8.5%. Mean long-term survival was 5.8 ± 0.56 years (range, 4 months-17 years), with a significant difference between primary or patch (mean, 6.5 years) and circumferential or extensive repair (mean, 4.2 years; P < .005). Cumulative (47% vs 52%) and mean (3.1 vs 3.6 years; P > .12) survival was similar between patients with single-segment and extensive IVC resection and replacement.
CONCLUSIONS: IVC resection and reconstruction for en bloc tumor excision is safe, even when extensive repairs are necessary. Replacement of the IVC with prosthetic graft avoids extremity venous complications and likely contributes to quality of survival. Survival depends on tumor behavior and degree of IVC involvement, where primary and patch repair has a better prognosis than circumferential resection.
Copyright © 2012 Society for Vascular Surgery. Published by Mosby, Inc. All rights reserved.

Entities:  

Mesh:

Year:  2012        PMID: 22386140     DOI: 10.1016/j.jvs.2011.11.054

Source DB:  PubMed          Journal:  J Vasc Surg        ISSN: 0741-5214            Impact factor:   4.268


  26 in total

1.  Ex vivo excision of retroperitoneal soft tissue tumors: A case report.

Authors:  Amir A Rahnemai-Azar; Adam D Griesemer; Monica L Velasco; Tomoaki Kato
Journal:  Oncol Lett       Date:  2017-08-23       Impact factor: 2.967

2.  Resection of the Inferior Vena Cava for Retroperitoneal Sarcoma: Six Cases and a Review of Literature.

Authors:  Joy Ghose; Rahul Bhamre; Nikhil Mehta; Ashwin Desouza; Shraddha Patkar; Jayesh Dhareshwar; Mahesh Goel; Shailesh V Shrikhande
Journal:  Indian J Surg Oncol       Date:  2018-07-19

3.  The enduring patency of primary inferior vena cava repair.

Authors:  Neel A Mansukhani; George E Havelka; Irene B Helenowski; Heron E Rodriguez; Andrew W Hoel; Mark K Eskandari
Journal:  Surgery       Date:  2016-12-20       Impact factor: 3.982

4.  Inferior Vena Cava Injuries: Sometimes Less is More.

Authors:  Eduardo Smith Singares
Journal:  Bull Emerg Trauma       Date:  2017-07

5.  The use of biological grafts for reconstruction of the inferior vena cava is a safe and valid alternative: results in 32 patients in a single institution.

Authors:  Carlo Pulitanó; Michael Crawford; Phong Ho; James Gallagher; David Joseph; Michael Stephen; Charbel Sandroussi
Journal:  HPB (Oxford)       Date:  2013-01-18       Impact factor: 3.647

6.  The Use of Autologous Peritoneum for Complete Caval Replacement Following Resection of Major Intra-abdominal Malignancies.

Authors:  Laurent Coubeau; Juan-Manuel Rico Juri; Olga Ciccarelli; Nicolas Jabbour; Jan Lerut
Journal:  World J Surg       Date:  2017-04       Impact factor: 3.352

7.  Current trends in vena cava reconstructive techniques with major liver resection: a systematic review.

Authors:  Maria Baimas-George; Christoph Tschuor; Michael Watson; Jesse Sulzer; Patrick Salibi; David Iannitti; John B Martinie; Erin Baker; Pierre-Alain Clavien; Dionisios Vrochides
Journal:  Langenbecks Arch Surg       Date:  2020-09-26       Impact factor: 3.445

8.  Usefulness of a recanalized umbilical vein for vascular reconstruction in pediatric hepatic surgery.

Authors:  Masato Shinkai; Kyoko Mochizuki; Norihiko Kitagawa; Hiroshi Take; Hidehito Usui; Kaori Nakamura Yamoto; Shogo Fujita; Youkatsu Ohhama
Journal:  Pediatr Surg Int       Date:  2016-04-15       Impact factor: 1.827

9.  Surgical resection and inferior vena cava reconstruction for treatment of the malignant tumor: technical success and outcomes.

Authors:  Hitoshi Goto; Munetaka Hashimoto; Daijiro Akamatsu; Takuya Shimizu; Noriyuki Miyama; Ken Tsuchida; Yuta Tajima; Noriaki Ohuchi
Journal:  Ann Vasc Dis       Date:  2014-03-15

10.  Sarcoma Resection With and Without Vascular Reconstruction: A Matched Case-control Study.

Authors:  George A Poultsides; Thuy B Tran; Eduardo Zambrano; Lucas Janson; David G Mohler; Matthew W Mell; Raffi S Avedian; Brendan C Visser; Jason T Lee; Kristen Ganjoo; E John Harris; Jeffrey A Norton
Journal:  Ann Surg       Date:  2015-10       Impact factor: 12.969

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.